Global Cord Blood Corporation (NYSE:CO) will look or acquisitions. Chief Financial Officer Bing Chuen Chen said, "The capital on hand, as you are aware, is in excess of RMB 6 billion and half of which or close to half of which are as the result of people electing to pay the upfront payment option, which results in deferred revenue. Fair to say that the company right now is in a relatively strong financial position to potentially withstand any potential regulatory changes in the cord blood banking industry in China as well as the -- our ability to potential take on additional acquisitions or diversification projects".